-
EP3630164
European procedure
Extract from the Register of European Patents
EP About this file: EP3630164
| EP3630164 - DULAGLUTIDE FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE [Right-click to bookmark this link] | Status | The patent has been granted Status updated on 21.07.2023 Database last updated on 16.07.2024 | |
| Former | Grant of patent is intended Status updated on 10.04.2023 | ||
| Former | Examination is in progress Status updated on 03.12.2020 | ||
| Former | Request for examination was made Status updated on 06.03.2020 | ||
| Former | The international publication has been made Status updated on 08.12.2018 | ||
| Former | unknown Status updated on 25.06.2018 | Most recent event Tooltip | 04.06.2024 | New entry: Communication of a notice of opposition and request to file observations + time limit | Applicant(s) | For all designated states Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US | [2020/15] | Inventor(s) | 01 /
BOTROS, Fady Talaat c/o Eli Lilly and Company P.O. Box 6288 Indianapolis, Indiana 46206-6288 / US | 02 /
LAKSHMANAN, Mark Chandrakant c/o Eli Lilly and Company P.O. Box 6288 Indianapolis, Indiana 46206-6288 / US | 03 /
TUTTLE, Katherine Rose c/o Eli Lilly and Company P.O. Box 6288 Indianapolis, Indiana 46206-6288 / US | 04 /
ZIMMERMANN, Alan George c/o Eli Lilly and Company P.O. Box 6288 Indianapolis, Indiana 46206-6288 / US | [2020/15] | Representative(s) | Boanas-Evans, Duncan Richard Eli Lilly and Company Limited 8 Arlington Square West Downshire Way Bracknell, Berkshire RG12 1PU / GB | [N/P] |
| Former [2023/34] | Kent, Lindsey Ruth Eli Lilly and Company Limited 8 Arlington Square West Downshire Way Bracknell, Berkshire RG12 1PU / GB | ||
| Former [2020/15] | Kent, Lindsey Ruth Eli Lilly and Company Limited Lilly Research Center Erl Wood Manor Sunninghill Road, Windlesham Surrey GU20 6PH / GB | Application number, filing date | 18730908.3 | 24.05.2018 | [2020/15] | WO2018US34278 | Priority number, date | US201762513556P | 01.06.2017 Original published format: US 201762513556 P | [2020/15] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2018222472 | Date: | 06.12.2018 | Language: | EN | [2018/49] | Type: | A1 Application with search report | No.: | EP3630164 | Date: | 08.04.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 06.12.2018 takes the place of the publication of the European patent application. | [2020/15] | Type: | B1 Patent specification | No.: | EP3630164 | Date: | 23.08.2023 | Language: | EN | [2023/34] | Search report(s) | International search report - published on: | EP | 06.12.2018 | Classification | IPC: | A61K38/26, A61K38/28, A61K45/06, A61P13/12, G01N33/68 | [2023/17] | CPC: |
A61K45/06 (EP,US);
A61K38/26 (EP,US);
A61K38/28 (EP,US);
A61K38/556 (US);
A61P13/12 (EP,US);
G01N33/6893 (EP,US);
|
| Former IPC [2020/15] | A61K38/26, A61K38/28, A61K45/06, A61P13/12 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/15] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | DULAGLUTID ZUR BEHANDLUNG VON CHRONISCHER NIERENERKRANKUNG | [2020/15] | English: | DULAGLUTIDE FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE | [2020/15] | French: | DULAGLUTIDE POUR LE TRAITEMENT DE MALADIES RÉNALES CHRONIQUES | [2020/15] | Entry into regional phase | 02.01.2020 | National basic fee paid | 02.01.2020 | Designation fee(s) paid | 02.01.2020 | Examination fee paid | Examination procedure | 14.11.2019 | Amendment by applicant (claims and/or description) | 02.01.2020 | Examination requested [2020/15] | 02.01.2020 | Date on which the examining division has become responsible | 02.12.2020 | Despatch of a communication from the examining division (Time limit: M06) | 11.06.2021 | Reply to a communication from the examining division | 09.08.2022 | Despatch of a communication from the examining division (Time limit: M04) | 14.12.2022 | Reply to a communication from the examining division | 11.04.2023 | Communication of intention to grant the patent | 14.07.2023 | Fee for grant paid | 14.07.2023 | Fee for publishing/printing paid | 14.07.2023 | Receipt of the translation of the claim(s) | Divisional application(s) | EP23188793.6 / EP4279925 | Opposition(s) | Opponent(s) | 01
23.05.2024
27.05.2024
ADMISSIBLE Generics [UK] Limited Building 4, Trident Place Mosquito Way Hatfield Hertfordshire AL10 9UL / GB Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB | [2024/27] |
| Former [2024/26] | |||
| Opponent(s) | 01
23.05.2024
Generics [UK] Limited Building 4, Trident Place Mosquito Way Hatfield Hertfordshire AL10 9UL / GB Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB | 05.06.2024 | Invitation to proprietor to file observations on the notice of opposition | Fees paid | Renewal fee | 02.06.2020 | Renewal fee patent year 03 | 31.05.2021 | Renewal fee patent year 04 | 31.05.2022 | Renewal fee patent year 05 | 31.05.2023 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | SM | 23.08.2023 | [2024/20] | Cited in | International search | [A]WO2011138421 (BOEHRINGER INGELHEIM INT [DE], et al); | by applicant | US7452966 | US2010196405 |